Congressmen Gonzalez, Marshall, Welch and Carter Introduce Pharmacy Benefit Manager Accountability Study Act of 2019
WASHINGTON – Today, Congressmen Vicente Gonzalez (TX-15), Dr. Roger Marshall (KS-01), Peter Welch (VT-At Large) and Buddy Carter (GA-01) introduced H.R. 3223, the Pharmacy Benefit Manger Accountability Study Act of 2019. This bipartisan bill directs the Government Accountability Office (GAO) to conduct a study on the role pharmaceutical benefit managers play in the pharmaceutical supply chain and serves as a companion to existing Senate efforts.
This study would equip lawmakers to provide realistic recommendations for legislative action to lower the cost of prescription drugs for consumers and payers, improve the efficiency of the pharmaceutical supply chain by lowering intermediary costs, increase competition and provide transparency in pharmacy benefit management.
“From day one, I promised South Texans I would take action to lower the price of prescription drugs and provide greater transparency in the drug supply chain,” said Congressman Gonzalez. “This bipartisan legislation will give us greater insight on how to more effectively conduct oversight and hold all major healthcare industry stakeholders accountable while lowering the prices of prescription drugs so no person is forced to choose between putting food on the table, paying their bills or buying necessary medications.”
The bill additionally would direct the GAO to narrow its scope to look at Federal Exchange data and amend the parameters of the study to provide a three-year timeline in order to include adequate time to ensure the GAO can provide accurate qualitative and quantitative date.
For information on the Pharmacy Benefit Manager Accountability Study Act, please visit Congress.gov.